This site is intended for healthcare professionals
Drug news

NICE recommends conditional use of Esbriet in specific population with idiopathic pulmonary fibrosis.- Roche.

Read time: 1 mins
Last updated:8th Feb 2018
Published:8th Feb 2018
Source: Pharmawand

The National Institute for Health and Care Excellence has published final guidelines recommending the use of Esbriet (pirfenidone), from Roche, as an option for treating idiopathic pulmonary fibrosis in adults only if:the person has a forced vital capacity (FVC) between 50% and 80% predicted, the company provides pirfenidone with the discount agreed in the patient access scheme and treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12-month period).

The committee noted that the evidence came from 4 randomised double-blind placebo-controlled phase III trials (CAPACITY 1, CAPACITY 2, ASCEND and SP3) and other observational data. The appraisal committee reviewed existing and new data on the clinical and cost effectiveness of pirfenidone, having considered evidence on the nature of idiopathic pulmonary fibrosis and the value placed on the benefits of pirfenidone by people with the condition, those who represent them, and clinical experts.

NICE said Esbriet could not be considered a cost-effective use of NHS resources for adults with mild to moderate IPF since the most plausible incremental cost-effectiveness ratio (ICER) lay somewhere between about �25,700 and �28,900 per quality-adjusted life years (QALY) gained compared with best supportive care, and was associated with uncertainties that had the potential to substantially increase this.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights